Buy Now
$4,123 $4,850
15% off
$4,840 $6,050
20% off
$5,845 $8,350
30% off
Buy now
Premium Report Details
Base Year: 2024
Companies covered: 16
Tables & Figures: 134
Countries covered: 19
Pages: 155
Download Free PDF

Transcatheter Embolization And Occlusion Devices Market
Get a free sample of this reportGet a free sample of this report Transcatheter Embolization And Occlusion Devices Market
Is your requirement urgent? Please give us your business email for a speedy delivery!
Transcatheter Embolization And Occlusion Devices Market Size
The global transcatheter embolization and occlusion devices market was valued at USD 5.3 billion in 2024 and is expected to exhibit growth at a CAGR of 8.3% from 2025 to 2034 period. The market for transcatheter embolization and occlusion (TEO) devices is witnessing strong growth due to an intersection of clinical, technological and demographic factors.
One of the most prominent factors is the increasing incidence of chronic diseases such as cancer, complicated pregnancies, vascular malformations and hemorrhagic disorders like hemophilia all of which tend to need specialized medical attention. With a global population that is aging, the need for quality of life procedures that lessen the invasiveness of surgery and duration of hospitalization is increasing which makes TEO devices favorable to both physicians and patients.
Furthermore, the rising cases of liver cancer and hepatocellular carcinoma especially in the Asia Pacific region has led to the increased use of embolization therapies such as transarterial chemoembolization (TACE). Newer catheter, medical imaging, and biocompatible material technologies have improved the safety and accuracy of procedures and embolization therapy, guaranteeing more procedures are performed. Also, the increase in women suffering from uterine fibroids and their preference for uterine fibroid embolization (UFE) instead of a hysterectomy has further improved the market.
The widening application of TEO devices in Neuro-interventions, especially treating cerebral aneurysms and arteriovenous malformations, also fosters market growth positively. Increased patient and healthcare professionals awareness of embolization entails shorter recovery periods and fewer complications, further driving the demand. Furthermore, favorable reimbursement policies in developed regions along with a growing supply of interventional radiologists and catheterization laboratories worldwide are increasing procedural volumes. Strategic mergers and collaborations by major companies with designed diversification policies in expected product portfolios and targeted emerging markets also widen the scope of market growth. Altogether these factors accelerate innovation and adoption, augmenting the TEO devices market.
Transcatheter embolization and occlusion (TEO) devices are advanced surgical instruments that help to control excessive or pathological blood flow in the blood vasculature system. These devices consist of coils, plugs, microspheres, and liquids which are delivered through a catheter and are ideal for treating tumors, aneurysms, arteriovenous malformations, and uterine fibroids. Like other embolization procedures, TEO procedures are associated with less surgical trauma and shortened recovery time.
Transcatheter Embolization And Occlusion Devices Market Trends
There is a notable shift toward these procedures, which is a powerful factor fueling the transcatheter embolization and occlusion (TEO) devices market. Both patients and healthcare professionals are choosing to opt for minimally invasive treatments when compared to conventional open surgeries. This preference is due to significantly reduced post-operative pain, shorter recovery periods, and a lower chance of complications. TEO procedures, which utilize small ports for catheters insertion and deliver embolic agents through selective blood vessels, epitomize these trends.
Impact of Tariff on the Market
Taxes on medical devices such as manufacturing and selling transcatheter embolization and occlusion (TEO) devices can have severe repercussions on the worldwide market since they raise the cost of production and marketing. Greater taxes on imports of raw materials or completed goods could result in higher selling prices which restricts access to users, particularly in low-cost sensitive areas. These expenditures may slow the rate of procurement by hospitals and healthcare centers, and consequently, adoption rates.
In addition, international conflict and changes in regulations might interrupt supply chains, causing delays in the availability of products and hampering growth in these markets. They will have no choice but to revise their outsourcing and production plans, for example, relocating to regions without tariffs in order to remain competitive.
Transcatheter Embolization And Occlusion Devices Market Analysis
Based on device type, the market is bifurcated as non coil and coils. The non coil segment is expected to drive business growth and expand at a CAGR of 8.6%, reaching over USD 6.7 billion by 2034.
Based on application, the transcatheter embolization and occlusion devices market is segmented as oncology, peripheral vascular disease, neurology, urology, and other applications. The oncology segment is expected to drive business growth and expand at a CAGR of 8.8%, reaching over USD 4.4 billion by 2034.
Based on end use, the transcatheter embolization and occlusion devices market is classified into hospitals, ambulatory surgical centers, and other end users. The hospitals segment dominated the market with a revenue share of 62.6% in 2024.
U.S. transcatheter embolization and occlusion devices market accounted for USD 1.8 billion in 2024 and is anticipated to grow at a CAGR of 7.4% between 2025 to 2034 period.
In Europe transcatheter embolization and occlusion devices market, the UK is projected to grow remarkably in the coming years.
China holds a dominant position in the Asia Pacific transcatheter embolization and occlusion devices market.
Transcatheter Embolization And Occlusion Devices Market Share
The top 5 companies in the market account for approximately 65% of market share, driven by their strong product portfolios, technological advancements, and extensive global distribution networks. As a result of spending a lot on research and development, performing strategic mergers and acquisitions, and innovating continuously, these other companies get to maintain their market position. Agile adoption of nex gen embolization technologies is made possible by strong clinical trial pipeline and the regulatory approvals it receives throughout several major areas.
Also, these companies enjoy established contacts with the hospitals, interventional radiologists, and even the healthcare systems as a whole, allowing these companies to enjoy passive product sales for long periods of time. They are also able to penetrate newly available markets internationally which have a growing surge in the requirements for minimally invasive operations. These dominant companies sustain industry standards as well as shape its dynamics by providing holistic solutions like delivery systems, imaging guidance tools, and most importantly, embolic agents which other companies have to comply with.
Transcatheter Embolization And Occlusion Devices Market Companies
Prominent players operating in the transcatheter embolization and occlusion devices industry include:
USPs
Transcatheter Embolization And Occlusion Devices Industry News:
The transcatheter embolization and occlusion devices market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 – 2034 for the following segments:
Click here to Buy Section of this Report
Market, By Device Type
Market, By Application
Market, By End Use
The above information is provided for the following regions and countries: